FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.
Read original at benzingaStocks · News reference
RBC Capital Maintains Outperform on DexCom, Raises Price Target to $90
RBC Capital analyst Kendall Au maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the price target from $85 to $90.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 31, 2026, 6:49 PM
- Checked
- Jul 31, 2026, 6:49 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Argus Research Maintains Buy on DexCom, Raises Price Target to $96
Argus Research analyst Steve Silver maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $86 to $96.
Read original at benzingaCanaccord Genuity Maintains Buy on DexCom, Raises Price Target to $90
Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $82 to $90.
Read original at benzingaCitigroup Maintains Buy on DexCom, Raises Price Target to $88
Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $84 to $88.
Read original at benzinga